Assessments | Prior to registration | Prior to randomisation (end of run-in period) | Months since randomisation |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | 6 | 9 | 12 | 18 | 24 | 30 | 36 | 42 | 48 | 54 | 60 | ||||
All cohorts | |||||||||||||||
Main assessments | Registration assessmentsa | ✓ | |||||||||||||
End of run-in assessmentb | ✓ | ||||||||||||||
Follow-up assessmentsc | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Intermittent assessments | VES-13 questionnaire (65 ≥ years at registration) |
✓ | ✓ | ||||||||||||
Cognitive assessment | ✓ | ✓ | ✓ | ||||||||||||
Blood tests | FBC, LFT, U&E & eGFR | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||
C-Reactive Protein (CRP) | ✓ | ✓ | ✓ | ||||||||||||
Fasting lipid profile | ✓ | ||||||||||||||
Other tests | Tumour and blood sample | ✓ | |||||||||||||
Breast cohort | |||||||||||||||
Imaging | Mammography | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||
Colorectal cohort | |||||||||||||||
Imaging and procedures | CT (chest/abdomen/pelvis) | ✓ | ✓ | ✓ | ✓ | ||||||||||
Colonoscopy | ✓ | ✓ | ✓ | ✓ | |||||||||||
Blood tests | CEA test | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Prostate cohort | |||||||||||||||
Blood tests | PSA | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Gastro-oesophageal cohort | |||||||||||||||
No cohort specific investigations |
Registration assessments include: eligibility, co-enrolment (if applicable), blood pressure, height, weight, blood results, concomitant medication and comorbidities.
End of run-in assessments include: symptoms and toxicity, adherence, blood pressure.
Follow-up assessments include: symptoms and toxicity, adherence, blood pressure, weight, concomitant medication.